Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Telix Pharmaceuticals ( (AU:TLX) ).
Telix Pharmaceuticals Limited has issued 91,168 fully paid ordinary shares following the acquisition of Lightpoint Medical and its SENSEI® radio-guided surgery business. This move, executed without disclosure under Part 6D.2 of the Corporations Act, signifies Telix’s strategic expansion in the radio-guided surgery market, potentially enhancing its industry positioning and stakeholder value.
More about Telix Pharmaceuticals
Telix Pharmaceuticals Limited operates in the biotechnology industry, focusing on the development and commercialization of diagnostic and therapeutic products. The company is known for its innovative solutions in the field of radio-guided surgery, particularly through its acquisition of Lightpoint Medical and its SENSEI® business.
YTD Price Performance: 29.94%
Average Trading Volume: 7,303
Technical Sentiment Signal: Sell
Current Market Cap: $6.41B
For detailed information about TLX stock, go to TipRanks’ Stock Analysis page.